Ronawk Announces the Launch of STELLα: A Groundbreaking Non-Clinical Contract Research Organization (CRO)

Overland Park, KS - Ronawk, a leading biotechnology company, proudly announces the launch of STELLα, a state-of-the-art non-clinical contract research organization (CRO) dedicated to driving innovation in the life sciences industry.

The addition of STELLα to Ronawk's portfolio represents a significant milestone in the company's growth and expansion, further solidifying its position as a strategic contributor to the region’s growing biotech ecosystem.

STELLα, which derives its name from the Latin and Greek words for "star" and "pillar," respectively, symbolizes the organization's commitment to illuminating and accelerating the path to scientific breakthroughs. With a focus on convenience, service, and quality, STELLα strives to provide an unparalleled experience for its clients.

"We are thrilled to introduce STELLα to the market, as it represents a new era of non-clinical research services," said A.J. Mellott, CEO and Co-Founder of Ronawk. "Our mission has always been to accelerate scientific discovery, and with the launch of STELLα, we can offer a comprehensive suite of services that cater to the unique needs of the region by helping our customers achieve their research goals more effciently and effectively."

STELLα's core services include tissue and cell culture, histology and immunolabeling, bio-characterization, and microscopy. In addition, the CRO offers partnering services such as animal studies and electrophysiology. These services are designed to support a wide range of research projects, from early-stage discovery to preclinical development.